Denosumab-induced hypocalcaemia in high bone turnover states of malignancy and secondary hyperparathyroidism from renal failure

Internal Medicine Journal

Volumn 43, Issue 11, 2013, Pages 1243-1246

  Farinola, N ^a   Kanjanapan, Y ^a  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

Calcium; Denosumab; Hyperparathyroidism; Hypocalcaemia; Osteoporosis; Renal insufficiency

Indexed keywords

ALBUMIN; ANTINUCLEAR ANTIBODY; BISPHOSPHONIC ACID DERIVATIVE; CALCIFEDIOL; CALCIUM; COLECALCIFEROL; DENOSUMAB; GLUCONATE CALCIUM; PARATHYROID HORMONE; VITAMIN D;

AGED; ARTICLE; BONE METASTASIS; BONE TURNOVER; CALCIUM BLOOD LEVEL; CASE REPORT; CHRONIC KIDNEY DISEASE; CONSTIPATION; DRUG DOSE INCREASE; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FEMALE; FRAGILITY FRACTURE; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HOSPITAL ADMISSION; HUMAN; HYPOCALCEMIA; HYPOTENSION; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LUPUS LIKE SYNDROME; MALE; MUSCLE CRAMP; OUTCOME ASSESSMENT; PATIENT TRANSPORT; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; QT PROLONGATION; SECONDARY HYPERPARATHYROIDISM; URETER STRICTURE; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

CALCIUM; DENOSUMAB; HYPERPARATHYROIDISM; HYPOCALCAEMIA; OSTEOPOROSIS; RENAL INSUFFICIENCY;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; BONE REGENERATION; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; HYPOCALCEMIA; RENAL INSUFFICIENCY;

EID: 84887714789     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/imj.12283     Document Type: Article

References (19)

1. Cummings SR, Martin JS, McClung MR, Siris ES, Eastell R, Reid IR etal. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361: 756-765.
2. Block G, Bone HG, Fang L, Lee E, Padhi D. A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res 2012; 27: 1471-1479.
3. Chapter 10.3.1, Bisphosphonates. In: Australian Medicines Handbook 2013. Adelaide: Australian Medicines Handbook Pty Ltd; 2013; 421-427.
4. Bone HB, Bolognese MA, Yuen CK, Kendler DL, Want H, Liu Y etal. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 2008; 93: 2149-2157.
5. McLean FC, Hastings AB. The state of calcium in the fluids of the body. I. The conditions affecting the ionization of calcium. J Biol Chem 1935; 108: 285-322.
6. Byrnes MC, Huynh K, Helmer SD, Stevens C, Dort JM, Smith RS. A comparison of corrected serum calcium levels to ionized calcium levels among critically ill surgical patients. Am J Surg 2005; 189: 310-314.
7. Jain A, Bhayana S, Vlasschaert M, House A. A formula to predict corrected calcium in haemodialysis patients. Nephrol Dial Transplant 2008; 23: 2884-2888.
8. Gauci C, Moranne O, Fouqueray B, de la Faille R, Maruani G, Haymann JP etal. Pitfalls of measuring total blood calcium in patients with CKD. J Am Soc Nephrol 2008; 19: 1592-1598.
9. Amgen Inc. Background Information for the Meeting of the Advisory Committee for Reproductive Health Drugs. Table 23. 2009 [cited 2013 Jul 7]. Available from URL:http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/reproductivehealthdrugsadvisorycommittee/ucm176623.pdf
10. Clinical Study Report 20040245. [cited 2013 July 7]. Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/125320s000MedR.pdf
11. Papapoulos S, Chapurlat R, Cesar L, Brandi ML, Brown JP, Czerwinski E etal. Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res 2012; 27: 694-701.
12. Huang JC, Sakata T, Pfleger LL, Bencsik M, Halloran BP etal. PTH differentially regulates expression of RANKL and OPG. J Bone Miner Res 2004; 19: 235-244.
13. Stopek AT, Lipton A, Body J-J, Steger GG, Tonkin K, de Boer RH etal. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010; 28: 5132-5139.
14. Healthy Canadians. Health Canada Endorsed Important Safety Information on XGEVA (denosumab). 2012 [cited 2013 Jul 7]. Available from URL: http://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2012/14811a-eng.php
15. Christakos S. Recent advances in our understanding of 1, 25-dihydroxyvitamin D(3) regulation of intestinal calcium absorption. Arch Biochem Biophys 2012; 523: 73-76.
16. National Kidney Foundation. KDOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42: S1-201.
17. Talreja D. Severe hypocalcaemia following a single injection of denosumab in a patient with renal impairment. J Drug Assess 2012; 1: 30-33.
18. Lai JKC, Lucas RM, Banks E, Ponsonby A-L, Ausimmune Investigator Group. Variability in vitamin D assays impairs clinical assessment of vitamin D status. Intern Med J 2012; 42: 43-50.
19. Cooper MS, Gittoes NLJ. Diagnosis and management of hypocalcaemia. Br Med J 2008; 336: 1298-1302.